GSK stock

GSK · LSE · GBp

Compare GSK
1,869.00 GBpChange from previous close: −3.14%Absolute change: −60.50 GBp

Close · November 17, 2026

Price history

+6.31% over the period

1 year: from 1,799.50 GBp (November 17, 2025) to 1,913.00 GBp (November 17, 2026), +6.31%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 17, 20261,913.00 GBp
October 30, 20261,855.00 GBp
September 30, 20261,832.00 GBp
August 28, 20261,853.50 GBp
July 31, 20261,931.50 GBp
June 30, 20261,981.00 GBp
May 29, 20261,881.50 GBp
April 30, 20261,928.50 GBp
March 31, 20262,064.00 GBp
February 27, 20262,201.00 GBp
January 30, 20261,876.50 GBp
December 31, 20251,824.50 GBp
November 28, 20251,791.00 GBp
November 17, 20251,799.50 GBp

At a glance

  • The company

    Develops and manufactures vaccines, specialty medicines, and general medicines to prevent and treat diseases globally

  • Latest results

    Quarter to September 30, 2026 · EPS £0.55 (estimate £0.51)

TickerLandia's take on GSK

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low1,690.00 GBp
52-wk high2,282.00 GBp

−18.10% from the 52-week high

Analysts · 23 analysts

Average target2,147.38 GBp+14.89% vs. price

Buy 7 · Hold 13 · Sell 3 · Hold

TickerLandia Fingerprint: GSK

Compared with similar companies: low growth, low price, and low financial strength.

Financials and price compared with 25 companies in the drug manufacturers - general industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

GSK is cheaper than in the past and cheaper than similar companies

On the latest fiscal year's earnings (2025), GSK's P/E today is 13.8, below the median of its last 10 fiscal years (17.2; between 3.93 and 84.6 from 2016 to 2025). GSK's P/E (trailing 12 months): 18.0, −16% against the median of a group of 10 similar companies (21.5).

P/E compared with its history

Compared with 10 similar companies

GSK's metrics compared with similar companies
MetricGSKPosition in the groupBand
P/E (trailing 12 months)18.0Low
Forward P/E10.3Low
Operating margin30.5%Middle
ROE28.3%Middle
Debt/equity1.30High

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: GSK. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

£8.89B

Latest quarter · Q3 2026

Net income

£1.54B

Latest quarter · Q3 2026

Quarterly net margin

17.4%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
£77.35B
P/E
18.0
EPS
107.00 GBp
Volume
3.7M
Daily trading
€147.98M
Dividend yield
3.69%
Last ex-dividend on November 12, 2026

How GSK is changing

All results
  • Revenue grew 6.0% a year on average over the last 5 years

  • Operating margin rose from 21.9% to 24.3%

  • Profits turn into cash: free cash flow equal to 129% of net income

Returns

GSK returns with dividends

£1,000 invested in GSK 5 years ago, on November 17, 2021, would be worth £1,520 today with dividends reinvested: +52.01% in total, +8.74% per year. On price alone it would be £1,218 (+21.81%).

PeriodGSKFTSE 100£1,000 becomes
1 month+3.13%+0.38%£1,031
6 months+0.35%+5.98%£1,003
Year to date+4.85%+8.80%£1,049
1 year+10.11%+11.68%£1,101
3 years+52.31%+43.99%£1,523
5 years+52.01%+48.20%£1,520
10 years+112.35%+59.02%£2,123

Over the last 6 months it has done better than 16% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. FTSE 100: price only. Calculate your investment

The chart in detail

GSK: technical analysis

GSK shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 18.9% below its highest close since January 1, 1990 (2,304.83 GBp, January 8, 1999).

Trend
No clear trend
RSI (14 sessions)
49
Between 30 and 70
vs 200-session average
−4.37%

Support and resistance

Price areas where GSK has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance2,053.35 GBp+9.86%2 touches, last on July 6, 2026
  2. Resistance1,979.75 GBp+5.93%2 touches, last on August 10, 2026
  3. Resistance1,910.14 GBp+2.20%7 touches, last on October 27, 2026
  4. Last price1,869.00 GBp
  5. Support1,852.00 GBp−0.91%2 touches, last on July 21, 2026
  6. Support1,804.00 GBp−3.48%2 touches, last on August 14, 2026
  7. Support1,778.00 GBp−4.87%5 touches, last on October 28, 2026

Volatility and risk

Over the last year it has moved roughly in line with the FTSE 100.

Beta (1 year) vs FTSE 100
1.00
Volatility (60 sessions, annualised)
26.4%
Largest fall in the last year
−23.48%

Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

GSK: seasonality

Average monthly price change over 37 years

−1.0%Jan+0.2%Feb+1.3%Mar+1.9%Apr−0.7%May+0.3%Jun+0.1%Jul+0.3%Aug+0.5%Sep+1.5%Oct−0.0%Nov+2.0%Dec

Over the last 37 years, the strongest month for GSK has been December: +1.95% on average, positive in 23 years out of 36. The weakest has been January: −0.98% on average, positive in 14 years out of 36. November, the current month, has been positive in 17 years out of 36 (−0.02% on average).

Show chart data
MonthAverageMedianPositive years
January−0.98%−1.32%14 of 36
February+0.20%+0.56%20 of 37
March+1.28%+0.68%22 of 37
April+1.88%+2.04%23 of 37
May−0.68%−0.67%17 of 37
June+0.25%+1.07%23 of 37
July+0.15%+0.09%19 of 37
August+0.31%+0.53%22 of 37
September+0.55%+0.24%21 of 37
October+1.46%+1.04%20 of 37
November−0.02%−0.56%17 of 36
December+1.95%+2.02%23 of 36

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

GSK and its competitors

Shingles, RSV and HPV vaccines, HIV medicines, and inhalers for asthma and COPD are the products most people associate with the group. Its work covers vaccines, specialty medicines and general medicines, and it also develops oral small-molecule therapies for oncology and inflammatory diseases. Customers are in the United Kingdom, the United States and other markets abroad, and its collaborations include an mRNA vaccine project with CureVac and a tuberculosis alliance with AN2 Therapeutics.

Headquarters
London, United Kingdom
Employees
66,841
Founded
1715
Chief executive
Luke Miels
GSK and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
GSKGSK$102.04B30.5%18.0+0.35%
SanofiSAN$116.52B22.3%25.5+17.04%
BayerBAYN$61.54B16.5%—+48.87%
Novo NordiskNOVO.B$184.87B50.8%11.2−7.92%
AstraZenecaAZN$287.12B25.8%26.6+1.25%
NovartisNOVN$305.16B34.0%32.6+14.23%

Same industry or related industries, similar size. Compare GSK with its competitors · Full profile